CervoMed Raises $10.5 Million in Private Placement
CervoMed Inc. announced a private placement expected to generate $10.5 million in gross proceeds. The company said the funds will extend its cash runway into the second quarter of 2027 and support efforts to secure a partner for Phase 3 development of neflamapimod in dementia with Lewy bodies.
insidermonkey.comCervoMed Inc. entered into a definitive securities purchase agreement for a private placement that is expected to generate approximately $10.5 million in upfront gross proceeds before fees and expenses. The financing was led by institutional healthcare investors and included participation from insiders.
Net proceeds will extend the company's anticipated cash runway into the second quarter of 2027.
The company stated its primary focus is to establish a partnership to advance neflamapimod into Phase 3 development for dementia with Lewy bodies. It also plans to advance the drug through upcoming clinical milestones in nonfluent variant primary progressive aphasia and amyotrophic lateral sclerosis.
The company reported alignment with the U.S. Food and Drug Administration on a potential registration path for neflamapimod in dementia with Lewy bodies, announced in November 2025. It obtained similar alignment with the Medicines and Healthcare products Regulatory Agency in the United Kingdom and the European Medicines Agency in January 2026.
CervoMed said a Phase 2a trial evaluating neflamapimod in nonfluent variant primary progressive aphasia is fully enrolled. It also plans to initiate the EXPERTS-ALS Phase 2a trial within the next six months. The company announced completion of a 39-week chronic toxicity study and the manufacture of an initial Phase 3 clinical drug batch.
It also reported a peer-reviewed publication that supports the drug's mechanism in dementia with Lewy bodies.
